The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects ofm-chlorophenylpiperazine

[1]  D. Hoyer,et al.  Competitive antagonism by recognised 5-HT2 receptor antagonists at 5-HT1C receptors in pig choroid plexus , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  J. Palacios,et al.  5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  S. Woods,et al.  Serotonin function in anxiety , 1987, Psychopharmacology.

[4]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[5]  K. Cunningham,et al.  Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). , 1994, European journal of pharmacology.

[6]  J. C. Winter.  The stimulus effects of serotonergic hallucinogens in animals. , 1994, NIDA research monograph.

[7]  D. Fiorella,et al.  Effects of chronic cocaine administration on the serotonergic system in the rat brain , 1993, Pharmacology Biochemistry and Behavior.

[8]  D. Goldman,et al.  Analysis of the 5-HT1C receptor and the serotonin uptake site in fawn-hooded rat brain. , 1993, European journal of pharmacology.

[9]  S. Woods,et al.  m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. , 1993, Archives of general psychiatry.

[10]  J. C. Winter,et al.  Discriminative stimulus properties of m-chlorophenylpiperazine , 1993, Pharmacology Biochemistry and Behavior.

[11]  J. G. Carver,et al.  The effects of 5-HT and m-chlorophenylpiperazine (m-CPP) on the efflux of [3H]-5-HT from human perfused platelets. , 1993, British journal of clinical pharmacology.

[12]  J. Woods,et al.  The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[13]  Scott Wetzler,et al.  m-Chlorophenylpiperazine as a probe of serotonin function , 1991, Biological Psychiatry.

[14]  D. Murphy,et al.  Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. , 1991, Pharmacological reviews.

[15]  R. Kahn,et al.  The MCPP challenge test in schizophrenia: Hormonal and behavioral responses , 1991, Biological Psychiatry.

[16]  G. Kennett,et al.  Potencies of antagonists indicate that 5‐HT1C receptors mediate 1–3(chlorophenyl)piperazine‐induced hypophagia , 1991, British journal of pharmacology.

[17]  E. Hollander,et al.  Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder , 1991, Psychiatry Research.

[18]  R. Kahn,et al.  Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks , 1990, Biological Psychiatry.

[19]  F. Colpaert,et al.  Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. , 1990, European journal of pharmacology.

[20]  W. Cahn,et al.  Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects , 1990, Psychiatry Research.

[21]  W. Soudijn,et al.  The concept of selectivity in 5-HT receptor research. , 1990, European journal of pharmacology.

[22]  C. P. Vandermaelen,et al.  Effects of a potential antipsychotic, BMY 14802, on firing of central serotonergic and noradrenergic neurons in rats. , 1990, European journal of pharmacology.

[23]  J. Brady,et al.  Stimulus functions of drugs and the assessment of abuse liability , 1990 .

[24]  D. Murphy,et al.  Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. , 1989, Endocrinology.

[25]  D. Murphy,et al.  Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[26]  I. Lucki,et al.  Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. , 1989, The Journal of pharmacology and experimental therapeutics.

[27]  S. Peroutka,et al.  1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain , 1989, Biological Psychiatry.

[28]  R. Griffiths,et al.  Asymmetrical cross‐generalization in drug discrimination with lorazepam and pentobarbital training conditions , 1989 .

[29]  P. Seeburg,et al.  Structure and functional expression of cloned rat serotonin 5HT‐2 receptor. , 1988, The EMBO journal.

[30]  M. Breeding,et al.  Putative selective 5-HT-2 antagonists block serotonin 5-HT-1c receptors in the choroid plexus. , 1988, The Journal of pharmacology and experimental therapeutics.

[31]  E. sanders-Bush,et al.  Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. , 1988, The Journal of pharmacology and experimental therapeutics.

[32]  T. Jessell,et al.  Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. , 1988, Science.

[33]  R. Kahn,et al.  Behavioral indications for serotonin receptor hypersensitivity in panic disorder , 1988, Psychiatry Research.

[34]  G. Kennett,et al.  Evidence that mCPP may have behavioural effects mediated by central 5‐HT1C receptors , 1988, British journal of pharmacology.

[35]  D. Hoyer.  Functional correlates of serotonin 5-HT1 recognition sites. , 1988, Journal of receptor research.

[36]  T. Insel,et al.  Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. , 1987, Archives of general psychiatry.

[37]  P. Conn,et al.  Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. , 1987, The Journal of pharmacology and experimental therapeutics.

[38]  F. Colpaert.  Drug Discrimination: Methods of Manipulation, Measurement, and Analysis , 1987 .

[39]  P. Conn,et al.  Agonist‐Induced Phosphoinositide Hydrolysis in Choroid Plexus , 1986, Journal of neurochemistry.

[40]  P. Conn,et al.  Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions. , 1985, The Journal of pharmacology and experimental therapeutics.

[41]  E. sanders-Bush,et al.  Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites. , 1984, The Journal of pharmacology and experimental therapeutics.

[42]  R. Glennon,et al.  Drug‐induced discrimination: A description of the paradigm and a review of its specific application to the study of hallucinogenic agents , 1983, Medicinal research reviews.

[43]  R. Fuller,et al.  Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine. , 1983, Life sciences.

[44]  S. Garattini,et al.  Plasma concentrations of trazodone and 1‐(3‐chlorophenyl)piperazine in man after a single oral dose of trazodone , 1982, The Journal of pharmacy and pharmacology.

[45]  S. Garattini,et al.  (—)‐m‐Chlorophenyl‐piperazine, a central 5‐hydroxytryptamine agonist, is a metabolite of trazodone , 1981, The Journal of pharmacy and pharmacology.

[46]  R. Fuller,et al.  Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats , 1981, Neuropharmacology.

[47]  A. Herbet,et al.  Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. , 1978, Molecular pharmacology.

[48]  J. C. Winter.  Drug-Induced Stimulus Control , 1978 .